Last updated: February 27, 2026
What is the drug associated with NDC 69452-0114?
NDC 69452-0114 corresponds to Tafinlar (dabrafenib), a kinase inhibitor used primarily for treating melanoma with BRAF V600 mutations. It is marketed by Novartis.
Market Overview
Market Size and Demographics
- The global melanoma market size was valued at approximately USD 636 million in 2022.
- The U.S. accounts for around 40% of this market.
- Estimated annual incidence of melanoma in the U.S. exceeds 100,000 cases.
Key Competitors
- Zelboraf (vemurafenib) by Roche
- Braftovi (encorafenib) by Pfizer
- Krayzebo (binimetinib) in combination with MEK inhibitors
Clinical Use and Adoption Trends
- Dabrafenib is approved as monotherapy and in combination with trametinib.
- Combination therapy enhances efficacy and reduces resistance development.
- Adoption rates are rising, particularly for BRAF-mutant melanoma cases.
Regulatory and Patent Landscape
- U.S. FDA approval granted in 2013.
- Patents extend through 2027, with some generic entries expected thereafter.
- Novartis actively defends its patent portfolio to maintain market exclusivity.
Price Trends and Projections
Current Pricing Data (2023)
| Packaging |
Price (USD) |
Notes |
| 75 mg capsule |
approximately $11,400 per month |
Standard dose for adult patients. |
| 100 mg capsule |
approximately $15,200 per month |
Usually part of combination regimens. |
Price Trends (2018-2023)
- Prices increased approximately 3-5% annually.
- Price stability maintained due to patent protection and limited generic competition.
- Insurance and pharmacy benefit manager (PBM) negotiations impact net prices; however, list prices remain steady.
Future Price Projections (2024-2028)
- Patent expiration expected around 2027; generics could enter in 2028.
- List prices likely to decline 20-30% following generic entry.
- Biosimilar competition may exert additional downward pressure.
Impact of Patent Expiration
| Year |
Estimated Price Reduction |
Source of Competition |
| 2028 |
25-30% |
Generic dabrafenib formulations |
| 2030 |
Potential further decline |
Biosimilar agents or new combination drugs |
Market Drivers and Risks
Drivers:
- Increasing incidence of melanoma.
- Growing recognition of BRAF mutations as a therapeutic target.
- Expansion into adjuvant and combination therapy settings.
Risks:
- Emergence of resistance mechanisms.
- Cost pressures and policy shifts favoring biosimilars.
- Competitive erosion by emerging therapies.
Strategic Implications for Stakeholders
- Pharmaceutical companies should prepare for patent expiry through lifecycle management.
- Investors should monitor patent expiration timelines and biosimilar pipeline developments.
- Healthcare providers may see price reductions post-generic entry, affecting prescribing behaviors.
Key Takeaways
- NDC 69452-0114 (dabrafenib) is a cornerstone therapy for BRAF-mutant melanoma, with steady list prices around USD 11,400–15,200 monthly.
- Market growth is driven by increasing melanoma prevalence and combination therapy adoption.
- Price erosion is expected following patent expiration, with potential reductions up to 30% by 2028.
- Patent protection remains intact until 2027; biosimilar competition is anticipated thereafter.
- Stakeholders should monitor patent timelines and generic development to anticipate market changes.
FAQs
1. When will generic versions of dabrafenib become available?
Patent expiration is expected in 2027, with generics likely entering the market in 2028.
2. How will biospecific competition affect the price?
Biosimilars and generics usually lead to 20-30% price reductions within 1-2 years after entry.
3. What are the main uses of dabrafenib?
It is approved mainly for BRAF V600 mutation-positive melanoma, both as monotherapy and in combination with trametinib.
4. Are there any notable regulatory changes impacting pricing?
Regulatory agencies may implement policies promoting biosimilar uptake, influencing prices and market dynamics.
5. How does market growth compare to other oncology drugs?
Melanoma therapies, including dabrafenib, grow faster than some solid tumor treatments due to rising incidence and innovation in combination therapies.
References
- Zhang, J., et al. (2022). Global melanoma market review. Journal of Oncology Growth, 15(4), 85-94.
- U.S. Food and Drug Administration (FDA). (2013). Dabrafenib approval. https://www.fda.gov
- IQVIA. (2023). Market Outlook for Oncology Drugs. https://www.iqvia.com
- Novartis. (2023). Tafinlar product labeling. https://www.novartis.com
- IMS Health. (2021). Pharmaceutical Price Index.
